Systemic Lupus Erythematosus (SLE)

Immunology
4
Pipeline Programs
7
Companies
9
Clinical Trials
4 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
0
2
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

6 companies ranked by most advanced pipeline stage

Cartesian Therapeutics
1 program
1
Descartes-08Phase 21 trial
Active Trials
NCT06038474Active Not RecruitingEst. Nov 2026
Pfizer
PfizerNEW YORK, NY
1 program
1
RapamycinPhase 24 trials
Active Trials
NCT00830466Completed22Est. Jan 2016
NCT00800722Completed21Est. Jun 2014
NCT00779194Completed99Est. Dec 2015
+1 more trials
Precision BioSciences
1 program
1
MC-1-50Phase 11 trial
Active Trials
NCT06892145Recruiting12Est. Feb 2028
Qihan Biotech
Qihan BiotechChina - Hangzhou
1 program
1
QT-019B Cell InjectionPhase 11 trial
Active Trials
NCT07444307RecruitingEst. Dec 2028
Bristol Myers Squibb
1 program
Current standard of care treatment optionsN/A1 trial
Active Trials
NCT07175285Recruiting223Est. Nov 2032
Alliance Pharmaceuticals
1 program
Lupus Landmark Study: A Prospective Registry and BiorepositoryN/A1 trial
Active Trials
NCT05934149Recruiting3,500Est. Dec 2035

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
Cartesian TherapeuticsDescartes-08
PfizerRapamycin
PfizerRapamycin
Qihan BiotechQT-019B Cell Injection
Precision BioSciencesMC-1-50
PfizerRapamycin
PfizerRapamycin
Bristol Myers SquibbCurrent standard of care treatment options
Alliance PharmaceuticalsLupus Landmark Study: A Prospective Registry and Biorepository

Clinical Trials (9)

Total enrollment: 3,907 patients across 9 trials

NCT06038474Cartesian TherapeuticsDescartes-08

Descartes-08 for Patients With Systemic Lupus Erythematosus

Start: Feb 2024Est. completion: Nov 2026
Phase 2Active Not Recruiting
NCT00779194PfizerRapamycin

Prospective Study of Rapamycin for the Treatment of SLE

Start: Oct 2008Est. completion: Dec 201599 patients
Phase 2Completed
NCT00286156PfizerRapamycin

Pilot Study of Rapamycin as Treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Start: Oct 2006Est. completion: Dec 201430 patients
Phase 1/2Completed
NCT07444307Qihan BiotechQT-019B Cell Injection

A Clinical Study of Dual-Target, Universal CAR-T Cell Therapy for Refractory Systemic Lupus Erythematosus

Start: Dec 2025Est. completion: Dec 2028
Phase 1Recruiting
NCT06892145Precision BioSciencesMC-1-50

Clinical Trial of CD19 Targeted CAR-T Cell in Refractory Adult SLE

Start: Jun 2025Est. completion: Feb 202812 patients
Phase 1Recruiting
NCT00830466PfizerRapamycin

A Randomized Trial to Study Combined Pulsed Dye Laser and Rapamycin Treatment of Port Wine Stain Birthmarks.

Start: Dec 2008Est. completion: Jan 201622 patients
Phase 1Completed
NCT00800722PfizerRapamycin

A Randomized Trial to Study Combined Pulsed Dye Laser and Rapamycin Treatment of Port Wine Stain Birthmarks.

Start: Nov 2008Est. completion: Jun 201421 patients
Phase 1Completed
NCT07175285Bristol Myers SquibbCurrent standard of care treatment options

A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants

Start: Oct 2025Est. completion: Nov 2032223 patients
N/ARecruiting
NCT05934149Alliance PharmaceuticalsLupus Landmark Study: A Prospective Registry and Biorepository

Lupus Landmark Study: A Prospective Registry and Biorepository

Start: Jun 2023Est. completion: Dec 20353,500 patients
N/ARecruiting

Related Jobs in Immunology

Regulatory Affairs Manager(Immunology), Korea

AbbVie
Seoul, Seoul
9h ago

Regional Sales Trainer - Rheumatology (Mid Atlantic/Central)

AbbVie
Remote
9h ago

Senior Area Business Specialist, Immunology - Detroit, MI - Johnson & Johnson Innovative Medicine

Johnson & Johnson
Detroit, Michigan, United States
23h ago

Product Specialist - Immunology

Johnson & Johnson
Kibbutz Shefayim, Center District, Israel
23h ago

Senior Clinical Trial Physician, Rheumatology

Bristol Myers Squibb
Princeton - NJ - US
23h ago
$309K - $374K/yr

Supply Chain and Procurement Controller

Ferring Pharmaceuticals
Hvidovre, Denmark
23h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

4 actively recruiting trials targeting 3,907 patients
7 companies competing in this space

Related Indications

Rheumatoid Arthritis(475)Psoriasis(206)Ulcerative Colitis(151)Atopic Dermatitis(144)Crohn's Disease(140)Systemic Lupus Erythematosus(85)Arthritis, Rheumatoid(61)Plaque Psoriasis(53)Crohn Disease(49)Ankylosing Spondylitis(33)